Skip to main content

Advertisement

Table 2 Univariate analysis of clinical and histopathologic prognostic factors for locoregional control

From: Tumor aromatase expression as a prognostic factor for local control in young breast cancer patients after breast-conserving treatment

  rt-PCR series
  n 10-year LRC (%)
[95% CI]
P a RR [95% CI]
Family history of breast cancer    1.0  
   No 42 70 [56–87]   1
   Yes 11 NA   1 [0.22–4.59]
Age (continuous variable)    0.38 0.94 [0.83–1.07]
Age (years; dummy variable)    0.57  
   > 35 16 73 [59–90]   1
   ≤ 35 37 60 [32–100]   1.37 [0.47–4.0]
Clinical tumor stage    0.71  
   cT1 31 70 [53–91]   1
   cT2 22 74 [56–96]   0.81 [0.28–2.39]
Histologic T stage    0.55  
   pT1 34 70 [54–91]   1
   pT2 14 70 [49–100]   0.71 [0.24–2.13]
Surgical margin    0.70  
   ≥ 3 mm 32 61 [43–86]   1
   < 3 mm 17 81 [64–100]   0.81 [0.27–2.37]
Lymphovascular invasion    0.78  
   Absent 33 71 [56–91]   1
   Present 17 71 [50–100]   1.18 [0.36–3.87]
Histologic N stage    0.54  
   pN0 31 63 [47–84]   1
   pN1 16 78 [53–100]   0.49 [0.13–1.77]
   pN2 6 80 [52–100]   0.77 [0.17–3.52]
Histologic type    0.14  
   Ductal 46 75 [63–90]   1
   Lobular 6 33 [7–100]   2.61 [0.72–9.53]
Estrogen receptors (ERs)    0.14  
   ER- 10 90 [73–100]   1
   ER+ 37 63 [47–85]   4.28 [0.55–33.27]
Progesterone receptors (PR)    0.84  
   PR- 9 71 [43–100]   1
   PR+ 38 69 [53–88]   1.18 [0.26–5.27]
Hormone receptors (HRs)    0.48  
   ER- and PR- 7 86 [63–100]   1
   ER+ or PR+ 40 67 [52–86]   2.1 [0.06–3.72]
Histopathologic index    0.59  
   Grade 1–2 14 64 [35–100]   1
   Grade 3 36 73 [59–91]   0.70 [0.39–5.19]
Systemic therapy    0.35  
   None 16 54 [33–86]   1
   ChT 23 85 [70–100]   0.47 [0.15–1.49]
   ChT + HT 14 43 [11–100]   0.48 [0.12–1.90]
Total RT doseb    0.27  
   ≥ 60 Gy 43 76 [59–97]   1
   < 60 Gy 13 50 [28–88]   1.8 [0.63–5.15]
  1. NA = not applicable; CI = confidence interval; RR = relative risk for locoregional recurrence. aP values pertain to the relative risks. bTotal dose of radiotherapy to the tumor bed (whole breast dose + boost dose).